News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 119
- Sources here
- 13
- Companies here
- 24
Search results
Stored financial headlines
Active search
119 matching headlines
Ticker or company: BEIMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BeiGene Ltd (49BA.DU) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for BeiGene Ltd (49BA.DU), including its current stock price, historical data, charts, key statistics, and performance overview. The stock is currently trading at 304.00 EUR, up 2.01%, with detailed valuation measures and comparisons to similar biotechnology …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
ONC|Beigene Ltd|Price:359.030|Chg%:+10.760
This article provides a comprehensive stock analysis of Beigene Ltd (ONC), highlighting its strong fundamentals, high growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and recent "Buy" ratings from analysts. The analysis also covers …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
BeOne Medicines (ONC) Stock Climbs As Profit Growth Meets BRUKINSA Reliance
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The company's pipeline …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
3 Healthcare Stocks Retail Investors Are Watching As Hiring Slows
The article highlights three healthcare stocks—Krystal Biotech (KRYS), BeOne Medicines (ONC), and Zevra Therapeutics (ZVRA)—that retail investors are watching due to resilient hiring and growth in the healthcare sector despite a general slowdown in private sector job creation. It provides an overview of each …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
UBS Group raises BeiGene (ONC.US) target price to $467, citing another earnings beat in the second quarter and naming it a top pick.
UBS Group has raised its target price for BeiGene (ONC.US) to $467, following the company's strong second-quarter earnings performance. The firm reiterated its "Buy" rating and named BeiGene as a top pick, citing its robust product pipeline and favorable market position. This upward revision …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beijer Ref expands Heritage Distribution platform into Canada with acquisition of Enertrak
Heritage Distribution Holdings ATLANTA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Heritage Distribution Holdings, Beijer Ref's North American distribution platform, is expanding into Canada through Beijer Ref's acquisition of Enertrak, a Montreal-based specialized distributor of a wide range of HVACR products serving contractors across Eastern …
BEIJ-B
main company
Sharemaestro market context
Trend signal active
52 weeks -23.5%
BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.71 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 29.6%. EPS of $2.05 for the same period compares to $0.84 a year ago. The reported revenue represents a surprise of …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
BeiGene's H1 Net Profit Surges 627% to 3.27 Billion Yuan; Full-Year Revenue Guidance Raised to 46.2 Billion Yuan
BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven primarily by strong global sales of its core product, Brukinsa. The company has also raised its full-year revenue guidance to a range of 44.9 billion …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect BeOne Medicines Ltd. - Sponsored ADR (ONC) to post quarterly earnings of $1.40 per share in its upcoming report, which indicates a year-over-year increase of 66.7%. Revenues are expected to be $1.66 billion, up 25.9% from the year-ago quarter. Over …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Beigene Ltd (ONC) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Beigene Ltd (ONC), assigning it a strong financial score of 9.13, which ranks it highly within the Biotechnology & Medical Research industry. The company demonstrated robust operating efficiency, with a significant year-over-year revenue increase of 35.46% and …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%
Earnings Preview: BeiGene to Report Financial Results Pre-market on August 05
BeiGene (NASDAQ: BGNE) is scheduled to report its Q2 2026 earnings before market open on Wednesday, August 5, 2026. Analysts expect the company to post an EPS of -$3.66 and revenue of $475.29 million. Over the last year, BeiGene has experienced 3 EPS increases …
ONC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.8%